Recently, immune checkpoint blockades (ICBs) such as pembrolizumab (anti-PD-1), and ipilimumab (anti-CTLA-4) are largely used in immunotherapy, showing almost complete tumor eradication in responders [12]. Here, CTLA4 is linked to neoplasm.